YmAbs (YMAB) Total Debt to Capital

Y-mAbs Therapeutics (YMAB) focuses on independently bringing oncology antibodies to market, limiting partnerships solely to regional distribution. The current price action for the total debt-to-equity ratio is 0.04, while the business generates revenue through the supply of Danyelza for the treatment of pediatric neuroblastoma via insurance reimbursements. This niche possesses exceptional macro-stability and is not subject to seasonal fluctuations or economic downturns.

Capital structure distinguishes sustainable business models from speculative assets. The unique radiopharmaceutical logistics of Y-mAbs Therapeutics (YMAB) involving express isotope delivery requires significant capital expenditures. The business's debt-to-equity ratio measures the proportion of borrowed funds within total financing. A low level for this indicator confirms financial independence and an absence of credit risks. Such a configuration provides the issuer with a high degree of solvency and long-term stability.